1-4 of 4
Catherine Berset
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Promising activity of nelfinavir-bortezomib-dexamethasone in proteasome inhibitor–refractory multiple myeloma

Clinical Trials & Observations
Christoph Driessen, Rouven Müller, Urban Novak, Nathan Cantoni, Daniel Betticher, Nicolas Mach, Axel Rüfer, Ulrich Mey, Panagiotis Samaras, Karin Ribi, Lenka Besse, Andrej Besse, Catherine Berset, Stephanie Rondeau, Hanne Hawle, Felicitas Hitz, Thomas Pabst, Thilo Zander
Journal: Blood
Blood (2018) 132 (19): 2097–2100.
https://doi.org/10.1182/blood-2018-05-851170
Published: 2018
Includes: Supplemental data
Journal Articles

The HIV Protease Inhibitor Nelfinavir in Combination with Bortezomib and Dexamethasone (NVd) Has Excellent Activity in Patients with Advanced, Proteasome Inhibitor-Refractory Multiple Myeloma: A Multicenter Phase II Trial (SAKK 39/13)

Christoph Driessen, MD PhD, Rouven Müller, MD, Urban Novak, MD, Nathan Cantoni, MD, Daniel Betticher, Nicolas Mach, Michael Gregor, Panagiotis Samaras, MD, Catherine Berset, Stephanie Rondeau, Hanne Hawle, MD, Felicitas Hitz, MD, Thomas Pabst, MD PhD, Thilo Zander, MD
Journal: Blood
Blood (2016) 128 (22): 487.
https://doi.org/10.1182/blood.V128.22.487.487
Published: 2016
Journal Articles

SAKK 65/08: A Phase I Dose Escalation Study of Bortezomib in Combination with Nelfinavir in Patients with Advanced Hematologic Malignancies

Christoph Driessen, MD, Jürgen Bader, Marianne Kraus, PhD, Markus Jörger, MD PhD, Hilde Rosing, PhD, Gregoire Berthod, MD, Felicitas Hitz, MD, Catherine Berset, PhD, Alexandros Xyrafas, Hanne Hawle, MD, Hermann S Overkleeft, PhD, Christiana Sessa, MD, Alwin Huitema, PhD, Ulrich JM Mey, Thomas Pabst, MD, Roger von Moos, MD, Dagmar Hess, MD
Journal: Blood
Blood (2014) 124 (21): 4747.
https://doi.org/10.1182/blood.V124.21.4747.4747
Published: 2014
Journal Articles

SAKK 65/08: A Phase I Trial of the HIV Protease Inhibitor Nelfinavir in Combination with Bortezomib Identifies Nelfinavir As FDA Approved, Oral Drug that Inhibits the Proteasome and Induces Proteotoxic Stress in Vivo and has Potential Antimyeloma Activity.

Christoph Driessen, MD, Dagmar Hess, MD, Thomas Pabst, MD, Sarah R Haile, Markus Joerger, MD, Roger von Moos, MD, Catherine Berset, Susanne Crowe, Hilde Rosing, PhD, Hermen S Overkleeft, Christiana Sessa, Marianne Kraus
Journal: Blood
Blood (2012) 120 (21): 2956.
https://doi.org/10.1182/blood.V120.21.2956.2956
Published: 2012